

I. Amendments to the Specification

On page 8, line 20 and on page 10, line 14, kindly amend the term “1,3-Dioxo-5-nitro-N-(pyrid-2-ylethyl)-1,2,3,4-tetrahydro[i]isoquinoline” to read “1,3-Dioxo-5-nitro-N-(pyrid-2-ylethyl)-1,2,3,4-tetrahydrobenzo[i]isoquinoline”.

On page 22, line 12, kindly amend the term “intrapertoneally” to read “intraperitoneally”.